

Dr LAM, Chi-leung David

October, 2018

Affiliations:

Division of Respiratory Medicine, Department of Medicine, Queen Mary Hospital, 102, Pokfulam Road, Pokfulam, Hong Kong
Phone: (852) 2255 5814, Email: dcllam@hku.hk

Academic and professional qualifications:

1993	BSc(BiomedSc)(Hon)(HK)	Department of Pathology, University of Hong Kong (HKU)
1995	MBBS (HK)	Faculty of Medicine, HKU
1999	MRCP (UK)	Member of the Royal College of Physicians, United Kingdom
2002	FHKCP	Fellow of the Hong Kong College of Physicians, HK
2002	FHKAM (Medicine)	Fellow of the Hong Kong Academy of Medicine, HK
2005	FCCP	Fellow of the American College of Chest Physicians, USA
2007	PhD (HK)	Molecular Pathology, Department of Pathology, HKU
2008	MRSB	Member of the Royal Society of Biology, UK
2008	FACP	Fellow of the American College of Physicians, USA
2010	FRCP (Edinburgh)	Fellow of the Royal College of Physicians of Edinburgh, UK
2012	FRCP (Glasgow)	Fellow of the Royal College of Physicians and Surgeons at Glasgow, UK
2013	FAPSR	Fellow of the Asian Pacific Society of Respiriology
2014	MD(HK)	Faculty of Medicine, HKU
2017	FRCP (London)	Fellow of the Royal College of Physicians of London

Current and previous appointments:

12.2017 – present	Clinical Associate Professor, Department of Medicine, HKU Honorary Consultant, Department of Medicine, QMH
12.2009 – 11.2017	Clinical Assistant Professor, Department of Medicine, HKU
10.2008 – 11.2009	Associate Consultant, Department of Medicine, Hong Kong West Cluster/QMH
7.1996 – 9.2008	Medical Officer, Department of Medicine, Hong Kong West Cluster/QMH

Honors and Awards

1	Sir Patrick Manson Gold Medal, Faculty of Medicine, University of Hong Kong	2014
2	Faculty Teaching Medal, Faculty of Medicine, University of Hong Kong	2013
3	APSR Travel Award to attend American Thoracic Society (ATS) Annual Conference	2010
4	Travel Award, 14 th Congress of the Asian-Pacific Society of Respiriology (APSR)	2009
5	AACR ITO-EN Ltd Scholar-in-training Award, American Association of Cancer Research (AACR)	2005
6	Japanese Respiratory Society Young Investigator Award	2005
7	Young Investigator Award (Cancer – Basic Science Group) Medical Research Conference, Medical Science Group, HKU	2004
8	The International Association on Study of Lung Cancer (IASLC) Young Investigator Award	2003
9	The Hong Kong Lung Foundation Fellowship	2002-03
10	The Hong Kong Thoracic Society Young Investigator Award	2002

Professional interests and expertise

Lung cancer - Molecular pathology, non-invasive diagnostics, interventional pulmonology, targeted therapies

COPD - Airway inflammation, smoking cessation, clinical trials

Professional activities:

Deputy Editor: *Respirology* 2015 – present

Editorial Board Members: *Respirology* 2012 – 2014; *Respirology Case Reports* 2014 – present

Chairperson, Education Committee, Asian Pacific Society of Respiriology (APSR)

Vice-President, Hong Kong Thoracic Society 2017 – 2019

Previous Grant Holdings:

1. Hong Kong Health and Medical Research Fund (HMRF) 2014

Application of an EGFR array for the detection of Epidermal Growth Factor Receptor (EGFR) gene mutation in patients with Non-small Cell Lung Cancer (NSCLC)

Selected publications in recent years

1. **Lam DC**, Girard L, Suen WS, Chung LP, Tin VP, Lam WK, Minna JD, Wong MP. Establishment and Expression Profiling of New Primary Lung Cancer Cell Lines from Chinese Smokers and Life-time Never-Smokers. *Journal of Thoracic Oncology* 2006; 1(9): 932 – 942.
2. **Lam DCL**, Girard L, Ramirez R, Chau WS, Suen WS, Sheridan S, Tin VPC, Chung LP, Wong MP, Shay JW, Gazdar AF, Lam WK, Minna JD. Expression of Nicotinic Acetylcholine Receptor Subunit Genes showed difference in expression pattern in smokers and non-smokers. *Cancer Research* 2007; 67(10): 4638 – 47.
3. **Lam DCL**, Xu A, Lam KSL, Lam B, Lam JCM, Lui MMS, Ip MSM. Serum A-FABP level is elevated in severe OSA and correlates with insulin resistance. *European Respiratory Journal* 2009; 33(2): 346-51.
4. **Lam DC**, Lui MMS, Lam JCM, Ong LHY, Lam KSL, Ip MSM. Prevalence and recognition of obstructive sleep apnea (OSA) in Chinese with type 2 diabetes mellitus. *CHEST* 2010; 138: 1101 – 1107.
5. **Lam DC**, Lam B, Wong MKY, Lu C, Au WY, Tse EWC, Leung AYH, Kwong YL, Liang RHS, Lam WK, Ip MSM, Lie AKW. Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation – a randomized double-blinded placebo-controlled study. *Bone Marrow Transplantation* 2011; 46 (12): 1551 – 56.
6. **Lam DC**, Minna JD. How do we safely get people to stop smoking? *Cancer Prev Res (Phila)*. 2011 Nov; 4(11): 1724-7.
7. Yam I, **Lam DC**, Chan K, Chung-Man Ho J, Ip M, Lam WK, Chan TK, Chan V. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. *J Thorac Oncol*. 2012 Jul; 7(7):1131-40.
8. **Lam DC**, Fong DYT, Yu WC, Ko FW, Lau AC, Chan JW, Choo KL, Mok TY, Tam CY, Ip MSM, Chan-yeung M. FEV3, FEV6 and their derivatives for detecting airflow obstruction in adult Chinese. *Int J Tuberc Lung Dis*. 2012 May;16(5):681-6.
9. Liang BM, **Lam DC**, Feng YL. Clinical applications of lung function testing: a revisit. *Respirology*. 2012 May; 17(4):611-9.
10. **Lam DC**, Hui CK, Ip MSM. Issues in pulmonary function testing for screening and diagnosis of COPD. *Current Opinion in Pulmonary Medicine* 2012; 18(2): 104 – 111.
11. Tam TC, Ho JC, Wong MK, Wong WM, Wang JK, Lam JC, Lui MM, Lam WK, Ip MS, **Lam DC**. Treatment Outcomes in Elderly with Advanced-stage Non-small Cell Lung Cancer. *LUNG* 2013; 191(6):645-654.
12. Luo SY, Sit AK, Sihoe AD, Suen WS, Au WK, Tang X, Ma ES, Chan WK, Wistuba II, Minna JD, Tsao SW, **Lam DC**. Aberrant Large Tumor Suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. *Lung Cancer* 2014; 85(2): 282 - 292
13. Schraufnagel DE, Blasi F, Drummond MB, **Lam DC**, Latif E, Rosen MJ, Sansores R, Van Zyl-Smit R; on behalf of the Forum of International Respiratory Societies. Electronic Cigarettes: A Position Statement of the Forum of International Respiratory Societies. *Am J Respir Crit Care Med*. 2014; 190(6): 611 - 618.
14. Fysh ET, Thomas R, Read C, Kwan B, Yap E, Horwood F, Lee P, Piccolo F, Shrestha R, Garske L, **Lam DC**, Rosenstengel A, Bint M, de Chaneet C, Murray K, Smith N, Lee GC. Protocol of the Australasian Malignant Pleural Effusion (AMPLE) Trial: A Multicentre Randomized Study Comparing Indwelling Pleural Catheter versus Talc Pleurodesis in Patients with Malignant Pleural Effusions. *BMJ Open* 2014 Nov; 4 (11): e006757.
15. **Lam DC**, Luo SY, Deng W, Cheung AL, Cheng GH, Lin CH, Sham PC, Wan TS, Tsao SW. Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. *Journal of OncoTargets and Therapy* 2015; 8: 195 – 209.
16. Prabhakar CN, Fong KM, Peake MD, **Lam DC**, Barnes DJ. The Effectiveness of Lung Cancer MDTs and the Role of Respiratory Physician. *Respirology* 2015; Aug; 20(6):884-8. doi: 10.1111/resp.12520
17. Lee CY, **Lam CL**, Pang SY, Lau KK, Teo KC, Chang RS, Chan KH. Clinical outcomes of generalized myasthenia gravis in Hong Kong Chinese. Submitted to the *Journal of Neuroimmunology* 2015 Dec 15;289:177-81. doi: 10.1016/j.jneuroim.2015.10.018..
18. Lim S, **Lam DC**, Muttalif AR, Yunus F, Wongtim S, Le Thi Tuyet L, Shetty V, Chu R, Zheng JP, Perng DW and de Guia T. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. *Asia Pacific Family Medicine* 2015; 14(1):4. doi: 10.1186/s12930-015-0020-9

19. **Lam DC**, Tam TC, Lau KM, Wong WM, Hui CK, Lam JC, Wang JK, Lui MM, Ho JC, Ip MS. EGFR Array for diagnostic detection of plasma EGFR mutation and association with survival outcomes in advanced stage lung cancer patients. *Clinical Lung Cancer* 2015 Nov;16(6):507-13. doi: 10.1016/j.clcc.2015.06.003
20. **Lam DC**, Chan SC, Mak JC, Freeman C, Ip MSM, Shum DK. S-maltoheptaose targets syndecan-bound effectors to reduce smoking-related neutrophilic inflammation. *Scientific Reports* 2015 Aug; 10; 5: 12945.
21. **Lam DC**, Fu KH, Luo SY, Lui MS, Chan KH, Wistuba II, Gao B, Tsao SW, Ip MS, Minna JD. Expression of nicotinic acetylcholine receptor subunit genes in bronchial epithelium correlates with lung function. *American Journal of Physiology – Lung Cell and Molecular Physiology* 2015; Nov 25:ajplung.00101.2015. doi: 10.1152/ajplung.00101.2015.
22. Thomas R, Fysh ETH, Smith NA, Lee P, Kwan BCH, Yap E, Horwood FC, Piccolo F, **Lam DCL**, Garske LA, Shrestha R, Kosky C, Read CA, Murray K, Lee YCG. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. *JAMA* 2017 Nov 21;318(19):1903-1912.
23. **Lam DCL****, Kwok HH, Yu WC, Ko FW, Tam CY, Lau AC, Fong DY, Ip MS. Serum CC16 levels correlates with smoking-related lung function decline. Submitted to *BMC Pulmonary Medicine* 2018 Mar 16;18(1):47.
24. Muruganandani S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, **Lam DCL**, de Chaneet CC, Rashid Ali MRS, Yap E, Tobin CL, Garske LA, Nguyen PT, Stanley C, Popowicz ND, Kosky C, Thomas R, Read CA, Budgeon CA, Feller-Kopman D, Maskell NA, Murray K, Lee YCG. Aggressive versus Symptom-guided Drainage of Malignant Pleural Effusion via Indwelling Pleural Catheters: The Australasian Malignant Pleural Effusion (AMPLE) Trial-2 randomized clinical trial. *Lancet Respiratory Medicine* 2018 (In press).
25. Chan HS, Ko FK, Chan JW, So LK, **Lam DC**, Chan VL, Tam CY, Yu WC. Co-morbidities, mortality and management of chronic obstructive pulmonary disease patients who required admissions to public hospitals in Hong Kong – computerized data collection and analysis. *International Journal of COPD* 2018; (In Press).

For Sponsored Clinical trials (as site PI)

1. An open label, multicentre, single-arm trial to assess the safety of afatinib for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s).
2. A Global Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study).
3. A randomised double-blind, double-dummy parallel group study to compare the efficacy and safety of fluticasone propionate / formoterol fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID versus salmeterol / fluticasone (Seretide®) 50/500 µg BID in subjects with chronic obstructive pulmonary disease (COPD). [FLT3510]
4. A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. [DYNAGITO]
5. A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with **chronic obstructive pulmonary disease**.
6. Randomized, double-blind, placebo-controlled, multicenter study comparing ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on 28 days off or 14 days on 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non-cystic fibrosis **bronchiectasis**.
7. A randomized, double-blind, 12-week treatment, parallel-group study to evaluate the efficacy and safety of QMF149 (150 µg/160 µg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 µg/500 µg b.i.d.) in patients with **chronic obstructive pulmonary disease** (CQMF149F2202)
8. A 6-month, double-blind, randomised, multicenter, multinational trial to investigate the effect of 500 µg roflumilast tablets once daily versus placebo on pulmonary function in patients with **COPD** (RO-2455-301-RD)
9. A randomised, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study

of budesonide formoterol (Symbicort® Turbuhaler® 160/4.5µg inhalation, 2 inhalations twice daily) added to tiotropium (Spiriva™ 18 µg inhalation, 1 inhalation once daily) compared with tiotropium (Spiriva™ 18 µg inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (**COPD**) patients.